cyrilzakka/clinical-trials huggingface dataset:
Virtual Yoga for Social Isolation and Loneliness in Rural Veterans

The overarching goal of this project is to decrease social isolation and loneliness through increased awareness and uptake of virtual yoga group classes among rural Veterans.


Eligibility Criteria:
Inclusion Criteria:

* Enrolled in VA Healthcare
* Residential address associated with VA Portland Health Care System that is "rural" or "highly rural; except among Collaborative Aging Research using Technology (CART) participants
* Valid contact info (mailing address, email, and phone number)
* High speed Internet access
* Positive screen for loneliness (NIH Toolbox Loneliness Scale Score greater or equal to 13)

Exclusion Criteria:

* Any VA or non-VA yoga visit in the preceding 12 months
* Visually or hearing impaired, or any mobility limitation that would impact computer/mobile device use, without availability of appropriate assistive devices
* Cognitive impairment, upcoming medical procedures, or significant unstable medical and psychiatric conditions that may limit study participation
Patient Registry: Partial Breast Irradiation

This is an Aurora Health Care system registry of patients receiving accelerated partial breast irradiation and external beam.


Eligibility Criteria:
Inclusion Criteria:

* Aurora patients who decide to undergo PBI treatment in the next 5-years or who have had PBI Treatment in the last ten-years. All such patients are female.

Exclusion Criteria:

* Patients not seen in an Aurora facility
Prizma Device Temperature Measurement

The purpose of the study is to evaluate the temperature measurements by the Prizma device.

Primary objective of this study is to compare the temperature measured by the PRIZMA to the oral and Armpit temperature measured by a gold standard device in order to develop and evaluate a skin to body temperature conversion table.

Secondary objective is to collect and compare data of ECG, Respiration and SpO2 collected from the Prizma device to the data collected from gold standard devices for reference of noise level and for future development of the PRIZMA device.

Eligibility Criteria:
Inclusion Criteria:

* Signed written informed consent
* Age above 18 years from both genders
* ASA physical status 1-4
* Hospitalized in internal ward

Exclusion Criteria:

* Abuse of alcohol or illicit drugs
* History of mental retardation or any mental disease
* Skin irritation / Atopic dermatitis or any other skin condition at the area of patients palms that might affect his/her ability to hold the device appropriately
Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain

The aim of this study is to demonstrate that the application of Kinesio Taping on a myofascial trigger point in the trapezius muscle able to cause a decrease of the pain and an increase of the cervical range of motion in patients diagnosed with cervical pain.

The use of Kinesio Taping has become very popular for the treatment of many musculoskeletal disorders in recent decades. Of the six variants of application that has the Kinesio Taping, the space correction technique is suggested for pain management. The increased space achieved with this variant decreases the pressure by raising the skin directly over the treatment area, reducing chemical irritation receptors and therefore pain. The aim of this study is to demonstrate that the application of this variant of Kinesio Taping on a myofascial trigger point in the trapezius muscle able to cause a decrease of the pain and an increase of the cervical range of motion in patients diagnosed with cervical pain. For this, the pressure pain threshold will be measured with a algometer on the trigger point, the perception of pain with a visual analog scale and the range of motion with a cervical goniometer.

Eligibility Criteria:
Inclusion Criteria:

* Agree to participate in the study (signed informed consent)
* Presence of active myofascial trigger point in upper trapezius.
* Presence of neck pain

Exclusion Criteria:

* Subjects in which not clearly identified myofascial trigger point in the upper trapezius .
* Subjects who suffer or have suffered pathologies of upper limb deformities or orthopedic injuries that can alter static and biomechanics of shoulder and neck.
* Subjects who suffer or have suffered rheumatic or neurological disease or chronic shoulder pain and/or neck
* Subjects diagnosed with fibromyalgia, myelopathy or radiculopathy.
* Subjects suffering from any psychiatric disorder (such as anxiety or depression).
* Subjects who have suffered post-traumatic alteration (whiplash type) or cervical surgery.
* Pregnancy risk of abortion.
* Have used analgesics in the 48 hours before participating in the study
* Subjects presenting any contraindications to the application of Kinesio Taping.
* Know the Kinesio Taping technique applied in the study.
* Be receiving physical therapy for any shoulder or neck pathology.
Effect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery

Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery.

Dexamethasone \& Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries.

Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response.

Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability.

The aim of this study is to compare the effect of preoperative intrathecal dexamethasone versus dexmedetomidine on paralytic ileus after major abdominal surgery.

Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery.

Dexamethasone \& Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries.

Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response.

Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability.

Eligibility Criteria:
Inclusion Criteria:

* • Age: 18-60 years.

  * Sex: both males and females.
  * ASA physical status: I and II.
  * Operation: Open major abdominal surgery.
  * The surgery has to involve gastrointestinal resection and/or anastomosis.

Exclusion Criteria:

* • History of abnormal bowl habit or bowel obstruction

  * Allergy to dexamethasone or dexmedetomidine
  * Electrolyte disturbance
  * Patient who receive any drugs known to influence gastrointestinal motility.
  * Mental disorders or inability to cooperate
  * Morbid obesity (BMI \> 40), pregnancy, lactation
  * Diabetes
  * After neoadjuvant chemotherapy.
  * History of use of any steroids within the last 3 months
  * Previous abdominal surgery, herniorrhaphy or unplanned secondary surgery
Patient Centered Communication Training to Reduce Antibiotic Use in Acute Respiratory Tract Infections

The purpose of this study is to evaluate the effectiveness of a short training program for general practitioners in patient-centered communication to reduce antibiotic prescription for acute respiratory tract infections (ARTI).

Acute respiratory tract infections (ARTI) constitute the most frequent reason for seeking ambulatory care and for the prescription of antibiotics, despite the mostly viral origin of ARTI. Antibiotic prescriptions for ARTI increase unnecessary drug expenditures and are the main reason for increasing drug resistance of common bacteria. Evidence from intervention studies shows that merely providing physicians with guidelines and educational material for the management of acute respiratory tract infections is not enough to reduce antibiotic prescriptions for these conditions. The main reasons for antibiotic prescription in ARTI are non-medical and related to the physician patient relationship, patients' expectations and beliefs about the benefit of antibiotics. Therefore patient-centered communication could be a promising approach to reduce the rate of antibiotic prescription in ambulatory care.

Comparison: General practitioners (GPs) trained in patient-centered communication in addition to evidence-based guidelines for diagnosis and treatment of ARTI compared to GPs just introduced to evidence-based guidelines.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Symptoms of an acute respiratory tract infection for \>1 and \<28 days

Exclusion Criteria:

* Patients without informed consent
* Not fluent in German
* Patients with a psychiatric disorder
* Patients with a recurrent respiratory system infection with antibiotic treatment in the previous 4 weeks
Student Anxiety & Stress Study

The present study is a randomized clinical trial of an emotional awareness and expression intervention (EAET) and a mindfulness meditation intervention (MMT) for Wayne State University students with anxiety and somatic symptoms. Each of these treatments will be compared to a wait list control condition and to one another to evaluate how well the treatments improve physical and psychological symptoms, stress, and interpersonal functioning of 120 Wayne State University students at 4-week and 8-weeks post-randomization. This research is intended to provide an evidence-based approach to working with emotions to improve both anxiety and somatic symptoms in young adults and will illuminate how EAET compares to the commonly used mindfulness training. It is hypothesized that both active interventions will be superior to no treatment, and differences between the two treatments will be explored.

Anxiety is an increasingly common condition among college students and is often accompanied by somatic symptoms. These conditions impair students' social, psychological, and academic functioning and outcomes. Although students are utilizing campus and community mental health centers at increasing rates, these resources are strained. The present study aims to test the efficacy of two brief treatment options for students.

Integrating techniques from several emotion-focused therapies, the investigators have developed and tested an intervention encouraging the awareness and expression of habitually suppressed or avoided emotions. This Emotional Awareness and Expression Therapy (EAET) has been evaluated with various patient populations including fibromyalgia, irritable bowel syndrome, chronic pelvic pain, and medically unexplained symptoms. Results of these trials suggest that the intervention is efficacious in improving physical and psychological well-being, and is equal to or superior to other psychological interventions for somatic conditions. The present study seeks to advance the EAET literature by evaluating the efficacy of the intervention for a broader population and by employing a strong and conceptually different comparison condition: mindfulness meditation training.

Eligibility Criteria:
Inclusion Criteria: university student, reporting at least moderate levels of anxiety (GAD-7) and somatic symptoms (PHQ-15) -

Exclusion Criteria: psychosis, lack of fluency with spoken and written English language

-
Is Prophylactic Antibiotics Necessary In Otherwise Healthy Adult Patients Undergoing Ureteroscopic Procedures for Ureteral Stones?

The present study aims to investigate the relative efficacy, safety and risk of a single-dose prophylaxis in otherwise healthy adult patients undergoing ureteroscopic procedures for ureteral stones.


Eligibility Criteria:
Inclusion Criteria:

* 100 otherwise healthy adult patients.
* Aged from 20 to 65 years.
* Undergoing ureteroscopic procedures for ureteral stones.

Exclusion Criteria:

* Have the urine road the infection before the surgical operation, the surgical operation once took antibiotics the first 2 week.
* Pregnant or the women been breast feeding.
Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates

Benign prostatic hyperplasia (BPH) is one of the most common diseases in men. As BPH progresses, surgical treatments often become necessary. Holmium enucleation of the prostate (HoLEP) is an established procedure in the surgical treatment of BPH, especially for medium to large prostates. The long learning curve, the length of surgery, and expensive equipment still limit the availability of HoLEP to a few specialized centers.

Recently, a new method for treating BPH called aquablation has become commercially available. This technique uses real-time ultrasound imaging in combination with a robotic high-pressure water jet programmed and guided by the surgeon to resect prostate tissue. A RCT has shown functional results similar to transurethral resection of the prostate (TURP) for small to medium size prostates .

However, so far there are no controlled studies assessing whether Aquablation provides patient reported and functional outcomes that are non-inferior compared to HoLEP in medium size to large prostates (the latter cannot be operated by TURP due to its size limitations).

As aquablation offers some obvious advantages compared to HoLEP regarding learning curve and operation time, the aim of this study is to test whether efficacy and safety of aquablation are non- inferior compared to HoLEP in patients with medium to large size prostates, which would clearly support the use of aquablation and change everyday clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Men ≥45 years of age

  * Patient must be a candidate for HoLEP
  * Refractory to medical therapy or patient is not willing to consider (further) medical treatment
  * Patient has a prostate size of at least 50 ml and not more than 150ml, measured by transrectal ultrasound (TRUS)
  * IPSS ≥12
  * QoL≥3
  * Qmax ≤ 15 ml/s with a minimum voided volume ≥ 125 ml or patient in urinary retention
  * Written informed consent

Exclusion Criteria:

* Neurogenic lower urinary tract dysfunction

  * Urethral stenosis
  * Preinterventionally proven adenocarcinoma of the prostate
  * Nickel allergy
  * Not able to complete questionnaires due to cognitive or thought disorders
  * Language skills insufficient for informed consent and / or completion of questionnaires
Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation

Diagnosis and treatment of sleep apnea with continuous positive airway pressure (CPAP) therapy has been shown to decrease arrhythmia recurrence in patients with AF following ablation. However, patients with AF undergoing ablation are not routinely screened for sleep apnea, despite an estimated sleep apnea prevalence of 25% in the general population, and perhaps higher among patients with AF. Home sleep testing is frequently used for evaluation of sleep apnea.

The American Academy of Sleep Medicine considers atrial fibrillation (AF) to be high risk for sleep disordered breathing, and recommends that those with AF be evaluated for sleep apnea in its clinical guidelines. However, this has not yet become standard practice. The primary reasons for this are that sleep apnea remains under-suspected and under-diagnosed by electrophysiology physicians treating patients with AF, overnight sleep studies are cumbersome and are frequently associated with patient discomfort and high cost, and a mechanism for coordinating sleep apnea screening and treatment referral has not been established in electrophysiology clinics.

The gold standard for the diagnosis of sleep apnea is overnight polysomnography, typically conducted in a sleep laboratory, which can be costly and cumbersome for patients. Home sleep studies are FDA-approved for the diagnosis of sleep apnea and offer patients the opportunity to be assessed in a more natural sleep environment, and often in a more timely manner.

It has been demonstrated that diagnosis and treatment of sleep apnea reduces the risk of arrhythmia recurrence following AF ablation to a level comparable to those without sleep apnea. The goal of this study is to examine the feasibility of screening all patients undergoing AF ablation for sleep apnea, and to refer those patients with sleep apnea for evaluation and treatment by a sleep specialist.

Eligibility Criteria:
Inclusion criteria for the study include:

1. Patients age 18 years and older.
2. Patients with the diagnosis of atrial fibrillation presenting for clinical ablation procedure.

Exclusion criteria for the study include:

1. Patients with an existing diagnosis of sleep apnea.
2. Patients who are unable to provide informed consent.
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea

The objective of this study is to demonstrate that metronidazole 1% topical gel is effective for the treatment of patients with moderate to severe rosacea.


Eligibility Criteria:
Inclusion Criteria:

1. Male or non-pregnant, non-lactating female, 18 years of age or older.
2. Signed informed consent form, which meets all criteria of current FDA regulations.
3. If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives).
4. Have moderate to severe facial rosacea.
5. Have a Baseline Investigator Global Evaluation Score of 3 or 4.

Exclusion Criteria:

1. Mild facial rosacea (less than 8 inflammatory lesions on the face) or very severe rosacea (more than 50 inflammatory lesions)
2. Patients with excessive facial hair (beards, sideburns, moustaches, etc.) that would interfere with the diagnosis or assessment of rosacea.
3. History of hypersensitivity or allergy to Metronidazole, or other ingredients of the formulation.
4. Use of oral retinoids (e.g. Accutane ®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed) within the 6 months prior to the baseline visit.
5. Use of the following within 1 month prior to the baseline visit:

   * Topical Retinoids to the face
   * Systemic antibiotics known to have an impact on the severity of facial Rosacea
   * Systemic Steroids
6. The use of anticoagulant therapy within 14 days prior to baseline.
7. The use of any antipruritics, including antihistamines within 24 hours of any study visits.
8. History of blood dyscrasia.
9. Ocular rosacea (e.g., conjunctivitis, blepharitis, keratitis) of sufficient severity to require topical or systemic antibiotics.
10. Any dermatological condition other than rosacea that in the Investigator's opinion may interfere with the evaluation of the Patient's rosacea (e.g., acne, psoriasis, dermatitis).
11. Females who are pregnant, lactating or likely to become pregnant during the study.
12. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study Patient at undue risk by participation.
13. Any Patient (male or female) who has started, or changed hormonal therapy within 3 months of the Baseline visit (this includes hormonal contraceptives).
14. Use of high strength (20% or above) alpha-hydroxy acid for facial peel or any type of chemical facial skin peel or other significant cosmetic procedures within 2 months of the study start.
15. Receipt of any drug as part of a research study within 30 days prior to dosing.
16. Employees of the research center or Investigator.
17. Previous participation in this study.
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

This study, designed as a proof of concept study of MCS110 in pigmented villonodular synovitis, assessed the clinical response to MCS110 treatment in Pigmented Villonodular Synovitis (PVNS) patients, after a single or multiple intravenous doses of MCS110, using magnetic resonance imaging to assess tumor volume, and evaluated the pharmacokinetics/pharmacodynamics, safety and tolerability in this population.


Eligibility Criteria:
Inclusion criteria:

* Males and Females aged ≥ 18 years (≥ 12 years in PART C) with PVNS or GCTTS with, at least, one measurable site of disease on MRI.
* Patients expected to get surgery (PART A of study only).
* Vital signs within the ranges: systolic blood pressure 80-150 mmHg , diastolic blood pressure 50-100 mmHg, pulse rate 40-100 bpm, oral body temperature 35.0-37.5°C.
* Patients with normal level of serum ionized calcium and phosphate.
* Women of child-bearing potential must use highly effective contraception during the study and for 84 days after the study drug infusion.

Exclusion criteria:

* Patients with major surgery less than 3 months prior to start study drug or who have still side effects of such therapy.
* Presence of systemic illness precluding definitive surgery or increasing the risk to patients due to potential immunosuppression.
* Use previously of intra-articular treatment within 4 weeks prior dosing.
* Patients with dermal change indicative of lymphedema or phlebolymphedema. disease.
* Patients with elevated troponin T and/or CK levels (\> 1.5 x ULN for the laboratory) or with history of myositis, rhabdomyolysis or other myopathic disease.
* Patients receiving immunosuppressive treatment as well as corticosteroids which cannot be discontinued at least 4 weeks before dosing.
* Patients engaged in a resistance exercise training program.
* Patients with pacemakers or any metallic objects as exclusion for MRI
* Patients with concomitant disease know to get influence on bone metabolism
* Patients who have history of drug or alcohol abuse within 12 months prior study dosing.
* Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply.
Paediatric Ards Neuromuscular Blockade Study

Paediatric acute respiratory distress syndrome (ARDS) is a manifestation of severe, life-threatening lung injury. Care for paediatric patient is mainly supportive and based on what works in adults and personal experiences, including the use of mechanical ventilation. However, differences in lung physiology and immunology between (young) children and adults suggests that adaptation of adult practices into paediatrics may not be justified. A study in adults with severe ARDS showed that early use of neuromuscular blocking agents (NMBA) improved 90-day survival and increased time off the ventilator without increasing muscle weakness. It is unknown if this is also true for paediatric ARDS


Eligibility Criteria:
Inclusion criteria

* Informed consent
* Age younger than 5 years
* Need for mechanical ventilation with tidal volume 5 - 8 mL/kg ideal bodyweight and PEEP equal to or greater than 5 cmH2O
* Early moderate - to - severe paediatric acute respiratory distress syndrome originating from any cause, i.e. acute onset of disease, and oxygenation index greater than 12, and one or more (bilateral) infiltrates on chest radiograph, and no evidence of left ventricular failure or fluid overload, and within the first 48 hours of PICU admission
* Sedation defined by Comfort - B scale between 9 - 12

Exclusion criteria

* No informed consent
* Known allergy or intolerance to rocuronium
* Continuous administration of neuromuscular blockade prior at the time of meeting the criteria for PARDS
* Chronic respiratory failure on home ventilation
* Intracranial hypertension
* Bone marrow transplantation
* Immunocompromised patients (congenital or acquired)
* Pre-existing pulmonary hypertension
* Congenital heart disease with left - to - right shunting
* Cyanotic congenital heart disease
* Expected duration of mechanical ventilation less than 48 hours
* Withdrawal of life - sustaining treatment